Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026
Summary
Ollin Biosciences raised an oversubscribed $330 million Series B to fund global Phase 3 trials of OLN324 in diabetic macular edema and wet AMD. The company said the program follows positive head-to-head proof-of-concept data and feedback from the FDA and EMA. Ollin also plans to advance OLN102 into clinical development this year. The financing strengthens its pipeline and supports expansion as it moves toward registrational studies.
Funding
Amount
$330.0M
Total raised
Date
June 24, 2026
Announcement date
Investors
T. Rowe Price, Commodore Capital, TCG Crossover, ARCH Venture Partners, The Blackstone Group LP, RA Capital Management, CPP Investments, Andreessen Horowitz
Lead investors
Company
ollin.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected